Literature DB >> 22086344

Initiation of statin therapy: are there age limits?

Dipan A Desai1, Sammy Zakaria, Pamela Ouyang.   

Abstract

Cardiovascular disease (CVD) is the leading cause of death, with a higher prevalence in older adults who form an increasing proportion of the population of the United States. Statin treatment reduces cardiovascular morbidity and mortality in middle-aged adults. However, few studies have included older individuals, particularly ages 80 years or older. We review recent publications regarding primary and secondary prevention of CVD with statin therapy in older adults. Risk scores and their limitations in this population are discussed. The association of adverse effects with intensive doses of statin and their interactions with other drugs may be more problematic in older adults. Statin therapy appears cost-effective for individuals with higher CVD risk but this is dependent on the assumptions used. Evidence remains limited regarding the overall benefit of starting statin therapy in adults ages 80 years and older; thus, clinical judgment remains necessary in making this decision.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22086344     DOI: 10.1007/s11883-011-0220-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  64 in total

1.  Weighing the benefits of high-dose simvastatin against the risk of myopathy.

Authors:  Amy Egan; Eric Colman
Journal:  N Engl J Med       Date:  2011-06-15       Impact factor: 91.245

Review 2.  Atorvastatin associated liver disease.

Authors:  A T Clarke; P R Mills
Journal:  Dig Liver Dis       Date:  2006-06-13       Impact factor: 4.088

3.  The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.

Authors:  Niteesh K Choudhry; Amanda R Patrick; Robert J Glynn; Jerry Avorn
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

Review 4.  Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.

Authors:  E J Mills; P Wu; G Chong; I Ghement; S Singh; E A Akl; O Eyawo; G Guyatt; O Berwanger; M Briel
Journal:  QJM       Date:  2010-10-07

5.  Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy.

Authors:  Doron Garfinkel; Derelie Mangin
Journal:  Arch Intern Med       Date:  2010-10-11

6.  Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥ 65 years old).

Authors:  Hiroshige Itakura; Noriaki Nakaya; Tadashi Kusunoki; Naokata Shimizu; Shunsaku Hirai; Seibu Mochizuki; Toshitsugu Ishikawa
Journal:  J Cardiol       Date:  2010-11-09       Impact factor: 3.159

Review 7.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Authors:  J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers
Journal:  BMJ       Date:  2009-06-30

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 9.  Management of hyperlipidemia in older adults.

Authors:  Karen P Alexander; Michael A Blazing; Robert S Rosenson; Elisabeth Hazard; Wilbert S Aronow; Sidney C Smith; E Magnus Ohman
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-01-05       Impact factor: 2.457

Review 10.  Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Authors:  Sydney B Long; Michael J Blaha; Roger S Blumenthal; Erin D Michos
Journal:  Clin Interv Aging       Date:  2010-12-22       Impact factor: 4.458

View more
  1 in total

1.  Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study.

Authors:  D Macías Saint-Gerons; C de la Fuente Honrubia; D Montero Corominas; M J Gil; F de Andrés-Trelles; F Catalá-López
Journal:  Eur J Clin Pharmacol       Date:  2013-09-24       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.